You just read:

Processa Pharmaceuticals Announces That It Has Been Assigned The License For The Clinical Stage Compound CTP-499 And Plans To Develop The Drug In Multiple Unmet Medical Need Conditions

News provided by

Processa Pharmaceuticals

Mar 21, 2018, 09:00 ET